GlaxoSmithKline Pharmaceuticals Limited (GLAXO.NS)

INR 2303.2

(-1.26%)

EBITDA Summary of GlaxoSmithKline Pharmaceuticals Limited

GlaxoSmithKline Pharmaceuticals Limited's latest annual EBITDA in 2023 was 8.87 Billion INR , up 1.14% from previous year.
GlaxoSmithKline Pharmaceuticals Limited's latest quarterly EBITDA in 2024 Q2 was 3.6 Billion INR , up 56.56% from previous quarter.
GlaxoSmithKline Pharmaceuticals Limited reported an annual EBITDA of 9.03 Billion INR in 2022, up 8.08% from previous year.
GlaxoSmithKline Pharmaceuticals Limited reported an annual EBITDA of 8.48 Billion INR in 2021, down -0.41% from previous year.
GlaxoSmithKline Pharmaceuticals Limited reported a quarterly EBITDA of 3.6 Billion INR for 2024 Q2, up 56.56% from previous quarter.
GlaxoSmithKline Pharmaceuticals Limited reported a quarterly EBITDA of 2.46 Billion INR for 2023 Q3, down -22.51% from previous quarter.

Annual EBITDA Chart of GlaxoSmithKline Pharmaceuticals Limited (2023 - 2004)

Historical Annual EBITDA of GlaxoSmithKline Pharmaceuticals Limited (2023 - 2004)

Year	EBITDA	EBITDA Growth
2023	8.87 Billion INR	1.14%
2022	9.03 Billion INR	8.08%
2021	8.48 Billion INR	-0.41%
2020	5.35 Billion INR	34.34%
2019	3.92 Billion INR	-10.81%
2018	7.31 Billion INR	24.69%
2017	5.77 Billion INR	14.43%
2016	5.37 Billion INR	-18.27%
2015	6.03 Billion INR	18.26%
2014	5.08 Billion INR	-27.85%
2013	7.31 Billion INR	-28.56%
2012	8.52 Billion INR	-14.04%
2011	9.54 Billion INR	26.63%
2010	8.89 Billion INR	17.76%
2009	7.77 Billion INR	30.72%
2008	7.17 Billion INR	15.49%
2007	6.43 Billion INR	26.7%
2006	5.86 Billion INR	28.65%
2005	5.08 Billion INR	-18.19%
2004	4.49 Billion INR	0.0%

Year	EBITDA	EBITDA Growth
2024 Q1	2.3 Billion INR	-20.36%
2024 Q2	3.6 Billion INR	56.56%
2023 Q3	2.46 Billion INR	-22.51%
2023 FY	- INR	1.14%
2023 Q4	2.57 Billion INR	4.51%
2023 Q1	1.8 Billion INR	-8.65%
2023 Q2	3.17 Billion INR	76.19%
2022 FY	- INR	8.08%
2022 Q2	2.78 Billion INR	57.99%
2022 Q1	1.76 Billion INR	-8.84%
2022 Q3	2.52 Billion INR	-9.6%
2022 Q4	1.97 Billion INR	-21.7%
2021 Q4	1.93 Billion INR	-6.96%
2021 Q1	1.83 Billion INR	-22.07%
2021 FY	- INR	-0.41%
2021 Q2	2.91 Billion INR	58.94%
2021 Q3	2.08 Billion INR	-28.6%
2020 Q1	1.71 Billion INR	117.83%
2020 FY	- INR	34.34%
2020 Q4	2.35 Billion INR	3.02%
2020 Q3	2.28 Billion INR	6.81%
2020 Q2	2.13 Billion INR	24.37%
2019 Q3	1.4 Billion INR	-32.87%
2019 FY	- INR	-10.81%
2019 Q4	789.57 Million INR	-43.96%
2019 Q1	1.96 Billion INR	-8.49%
2019 Q2	2.09 Billion INR	7.03%
2018 Q2	1.8 Billion INR	13.84%
2018 FY	- INR	24.69%
2018 Q4	2.14 Billion INR	39.39%
2018 Q3	1.53 Billion INR	-14.61%
2018 Q1	1.58 Billion INR	0.0%
2017 FY	- INR	14.43%
2017 Q1	334.3 Million INR	0.0%
2016 FY	- INR	-18.27%
2015 FY	- INR	18.26%
2014 FY	- INR	-27.85%
2013 FY	- INR	-28.56%
2012 FY	- INR	-14.04%
2011 FY	- INR	26.63%
2010 FY	- INR	17.76%
2009 FY	- INR	30.72%
2008 FY	- INR	15.49%
2007 FY	- INR	26.7%
2006 FY	- INR	28.65%
2005 FY	- INR	-18.19%
2004 FY	- INR	0.0%

Peer EBITDA Comparison of GlaxoSmithKline Pharmaceuticals Limited

Name	EBITDA	EBITDA Difference
Abbott India Limited	16.97 Billion INR	47.738%
Cipla Limited	67.19 Billion INR	86.795%
Gland Pharma Limited	13.33 Billion INR	33.44%
Kopran Limited	744.13 Million INR	-1092.387%
Marksans Pharma Limited	4.58 Billion INR	-93.49%
NGL Fine-Chem Limited	678.68 Million INR	-1207.377%
Pfizer Limited	8.23 Billion INR	-7.711%
Sanofi India Limited	8.86 Billion INR	-0.056%
SMS Pharmaceuticals Limited	1.21 Billion INR	-632.824%
TTK Healthcare Limited	999.34 Million INR	-787.88%